Abstract：
Cancer remains a leading cause of death worldwide, partly owing to late detection which entails limited and often ineffective therapeutic options. Most cancers lack validated screening procedures, and the ones available disclose several drawbacks, leading to low patient compliance and unnecessary workups, adding up the costs to healthcare systems. Hence, there is a great need for innovative, accurate, and minimally invasive tools for early cancer detection. In recent years, multi-cancer early detection (MCED) tests emerged as a promising screening tool, combining molecular analysis of tumor-related markers present in body fluids with artificial intelligence to simultaneously detect a variety of cancers and further discriminate the underlying cancer type. Herein, we aim to provide a highlight of the variety of strategies currently under development concerning MCED, as well as the major factors which are preventing clinical implementation. Although MCED tests depict great potential for clinical application, large-scale clinical validation studies are still lacking.
摘要：
癌症仍然是全球死亡的主要原因，部分原因是晚期检测，这需要有限且通常无效的治疗选择。大多数癌症缺乏经过验证的筛查程序，现有的方法揭示了几个缺点，导致患者依从性低和不必要的检查，加起来医疗保健系统的成本。因此，非常需要创新，准确,和用于早期癌症检测的微创工具。近年来,多癌早期检测（MCED）测试成为一种有前途的筛查工具，将体液中存在的肿瘤相关标志物的分子分析与人工智能相结合，以同时检测多种癌症并进一步区分潜在的癌症类型。在这里，我们的目标是突出目前正在制定的关于MCED的各种策略，以及阻碍临床实施的主要因素。虽然MCED测试显示了巨大的临床应用潜力，目前仍缺乏大规模的临床验证研究.
